Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
68 participants
INTERVENTIONAL
2019-03-25
2023-07-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Individualized Closed Loop TMS for Working Memory Enhancement
NCT04402294
Effects of rTMS on Human Brain Activity Measured With fMRI
NCT03259568
Effects of rTMS on Human Brain Activity
NCT04242810
Closed-loop rTMS-EEG During Visuomotor Integration.
NCT07249801
Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)
NCT06214065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Visit 1 has both remote and in-person procedures. The remote part of visit 1 will consist of a consenting and extended screening visit. The in-person procedures of visit 1 will be scheduled for the same day as visit 2. Before visit 2, the investigators will demonstrate TMS to make sure participants can tolerate the stimulation.
Visit 2 consists of an hour-long baseline MRI Scan along with an assessment session. The baseline MRI scan is used to find individualized TMS targets. The assessment session of visit 2 will be done over a video call. During the video call, the investigators will have the participant complete some computerized tasks and assessments.
Visit 3 will be a 1-hour long TMS/fMRI session, where the participant will complete a working memory task twice while single pulse TMS is being delivered. In between the 2 rounds of the working memory task, the participant will receive 4 minutes of repetitive stimulation.
Non-symptomatic subjects will have a fourth visit that mirrors visit 3.
Visit 5 or Visit 4 for ADHD participants, will take place if behavioral task is available, otherwise study participation will be considered complete. During the optional visit, participants may complete behavioral tasks during an MRI scan. No TMS will be administered during the final visit.
Participants will receive the compensation at the end of their participation. Payment may be given earlier if the participant withdraws from the study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
CROSSOVER
ADHD participants will have TMS administered to only their high regional controllability target.
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High regional controllability TMS target in non-symptomatic participants
We will administer TMS to an individualized target of high regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
High controllability TMS target
Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
Low controllability TMS target in non-symptomatic participants
We will administer TMS to an individualized target of low regional controllability while non-symptomatic participant completes a working memory task inside the MRI scanner.
Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
High regional controllability TMS target in ADHD participants
We will administer TMS to an individualized target of high regional controllability while patient completes a working memory task inside the MRI scanner.
Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
High controllability TMS target
Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transcranial Magnetic Stimulation (TMS)
Transcranial Magnetic Stimulation (TMS) is a non-invasive form of brain stimulation. TMS can influence activity in various brain regions, and it allows researchers to test or modify brain circuit communication.
High controllability TMS target
Administer TMS to a brain regions with high regional controllability while the subject engages in a working memory task.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Right-handed
* No history of schizophrenia or bipolar disorder
* No history of neurological illness
* Healthy participants: no history of any mental illness
* ADD/ADHD Participants; Diagnosed with ADD/ADHD
* ADD/ADHD: Ability to refrain from stimulant medication within 24 hours of study sessions
* For participants reporting daily use of more than 400mg caffeine/ day: willing to lower down to this level at least 1 week prior to screening visit and maintain throughout study visits
Exclusion Criteria
* Unable to receive or tolerate TMS
* Pregnant, nursing, or trying to become pregnant (self-attestation alone)
* History of stoke, epilepsy, or brain scarring
* Healthy participants: psychoactive medication use
* Healthy participants: first degree relative with psychosis
* ADHD participants: inability to refrain from stimulant medication within 23 hours of study sessions
* Active suicidality or current suicidal risk as determined by the investigator
* Any medication that interferes with fMRI recordings as per PI discretion
* Otherwise determined by investigator to be unfit for study
18 Years
28 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Institute of Mental Health (NIMH)
NIH
University of Pennsylvania
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
830174
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.